Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Expanding the frontiers of existing antiviral drugs : Possible effects of HIV-1 protease inhibitors against SARS and avian influenza

Identifieur interne : 004E27 ( Main/Exploration ); précédent : 004E26; suivant : 004E28

Expanding the frontiers of existing antiviral drugs : Possible effects of HIV-1 protease inhibitors against SARS and avian influenza

Auteurs : Andrea Savarino [Italie]

Source :

RBID : Pascal:05-0475002

Descripteurs français

English descriptors

Abstract

When unexpected diseases such as the severe acute respiratory syndrome (SARS) and avian influenza become a serious threat to public health, an immediate response is imperative. This should take into consideration existing licensed antiviral drugs against other viral diseases already known to be safe for use in humans. In this report, evidence is presented that HIV-1 protease inhibitors (Pis) currently used in anti-HIV-1 therapies might exert some effects on SARS and perhaps, on avian influenza. Evidence for the potential benefits of PIs against the SARS coronavirus (SARS-CoV) is provided by empirical clinical studies, in vivo viral inhibition assays and computational simulations of the docking of these compounds to the active site of the main SARS-CoV protease. As suggested by in silico docking of these molecules to a theoretical model of a subunit of type A influenza virus RNA-dependent RNA polymerase, there also exists a remote possibility that these PIs may have an effect on avian influenza viruses. Although this evidence is still far from being definitive, the results so far obtained suggest that PIs should be seriously taken into consideration for further testing as potential therapeutic agents for SARS and avian influenza.

Url:


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Expanding the frontiers of existing antiviral drugs : Possible effects of HIV-1 protease inhibitors against SARS and avian influenza</title>
<author>
<name sortKey="Savarino, Andrea" sort="Savarino, Andrea" uniqKey="Savarino A" first="Andrea" last="Savarino">Andrea Savarino</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Laboratory of Viral Immunology, Department of Infectious Diseases, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8</s1>
<s2>00168 Rome</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName>
<settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">05-0475002</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0475002 INIST</idno>
<idno type="RBID">Pascal:05-0475002</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000585</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000405</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000652</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000652</idno>
<idno type="wicri:doubleKey">1386-6532:2005:Savarino A:expanding:the:frontiers</idno>
<idno type="wicri:Area/Main/Merge">005172</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108403</idno>
<idno type="RBID">PMC:7108403</idno>
<idno type="wicri:Area/Pmc/Corpus">001118</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001118</idno>
<idno type="wicri:Area/Pmc/Curation">001118</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001118</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001341</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001341</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15893956</idno>
<idno type="wicri:Area/PubMed/Corpus">002738</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002738</idno>
<idno type="wicri:Area/PubMed/Curation">002738</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002738</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002715</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002715</idno>
<idno type="wicri:Area/Ncbi/Merge">000F51</idno>
<idno type="wicri:Area/Ncbi/Curation">000F51</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000F51</idno>
<idno type="wicri:doubleKey">1386-6532:2005:Savarino A:expanding:the:frontiers</idno>
<idno type="wicri:Area/Main/Merge">004B32</idno>
<idno type="wicri:Area/Main/Curation">004E27</idno>
<idno type="wicri:Area/Main/Exploration">004E27</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Expanding the frontiers of existing antiviral drugs : Possible effects of HIV-1 protease inhibitors against SARS and avian influenza</title>
<author>
<name sortKey="Savarino, Andrea" sort="Savarino, Andrea" uniqKey="Savarino A" first="Andrea" last="Savarino">Andrea Savarino</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Laboratory of Viral Immunology, Department of Infectious Diseases, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8</s1>
<s2>00168 Rome</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName>
<settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Journal of clinical virology</title>
<title level="j" type="abbreviated">J. clin. virol.</title>
<idno type="ISSN">1386-6532</idno>
<imprint>
<date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Journal of clinical virology</title>
<title level="j" type="abbreviated">J. clin. virol.</title>
<idno type="ISSN">1386-6532</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Antiretroviral agent</term>
<term>Antiviral</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Avian influenza</term>
<term>Birds</term>
<term>Coronavirus</term>
<term>HIV Protease Inhibitors (therapeutic use)</term>
<term>HIV-1 virus</term>
<term>Humans</term>
<term>Influenza A</term>
<term>Influenza A virus</term>
<term>Influenza in Birds (drug therapy)</term>
<term>Microbiology</term>
<term>Models, Molecular</term>
<term>Molecular Sequence Data</term>
<term>Molecular Structure</term>
<term>Peptidases</term>
<term>RNA-directed RNA polymerase</term>
<term>SARS Virus (drug effects)</term>
<term>Sequence Alignment</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe acute respiratory syndrome</term>
<term>Virology</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Alignement de séquences</term>
<term>Animaux</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Données de séquences moléculaires</term>
<term>Grippe chez les oiseaux (traitement médicamenteux)</term>
<term>Humains</term>
<term>Inhibiteurs de protéase du VIH (usage thérapeutique)</term>
<term>Modèles moléculaires</term>
<term>Oiseaux</term>
<term>Structure moléculaire</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Séquence d'acides aminés</term>
<term>Virus de la grippe A</term>
<term>Virus du SRAS ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antiviral Agents</term>
<term>HIV Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Influenza in Birds</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Grippe chez les oiseaux</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Antiviraux</term>
<term>Inhibiteurs de protéase du VIH</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Birds</term>
<term>Humans</term>
<term>Influenza A virus</term>
<term>Models, Molecular</term>
<term>Molecular Sequence Data</term>
<term>Molecular Structure</term>
<term>Sequence Alignment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Alignement de séquences</term>
<term>Animaux</term>
<term>Données de séquences moléculaires</term>
<term>Humains</term>
<term>Modèles moléculaires</term>
<term>Oiseaux</term>
<term>Structure moléculaire</term>
<term>Séquence d'acides aminés</term>
<term>Virus HIV1</term>
<term>Coronavirus</term>
<term>Antiviral</term>
<term>Peptidases</term>
<term>Antirétroviral</term>
<term>RNA-directed RNA polymerase</term>
<term>Microbiologie</term>
<term>Virologie</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Grippe A</term>
<term>Grippe aviaire</term>
<term>Virus de la grippe A</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">When unexpected diseases such as the severe acute respiratory syndrome (SARS) and avian influenza become a serious threat to public health, an immediate response is imperative. This should take into consideration existing licensed antiviral drugs against other viral diseases already known to be safe for use in humans. In this report, evidence is presented that HIV-1 protease inhibitors (Pis) currently used in anti-HIV-1 therapies might exert some effects on SARS and perhaps, on avian influenza. Evidence for the potential benefits of PIs against the SARS coronavirus (SARS-CoV) is provided by empirical clinical studies, in vivo viral inhibition assays and computational simulations of the docking of these compounds to the active site of the main SARS-CoV protease. As suggested by in silico docking of these molecules to a theoretical model of a subunit of type A influenza virus RNA-dependent RNA polymerase, there also exists a remote possibility that these PIs may have an effect on avian influenza viruses. Although this evidence is still far from being definitive, the results so far obtained suggest that PIs should be seriously taken into consideration for further testing as potential therapeutic agents for SARS and avian influenza.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Italie</li>
</country>
<region>
<li>Latium</li>
</region>
<settlement>
<li>Rome</li>
</settlement>
</list>
<tree>
<country name="Italie">
<region name="Latium">
<name sortKey="Savarino, Andrea" sort="Savarino, Andrea" uniqKey="Savarino A" first="Andrea" last="Savarino">Andrea Savarino</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E27 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004E27 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:05-0475002
   |texte=   Expanding the frontiers of existing antiviral drugs : Possible effects of HIV-1 protease inhibitors against SARS and avian influenza
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021